The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The vasomotor menopausal symptoms (vms) treatment market size has experienced significant expansion in recent years. It is anticipated to increase from $19.01 billion in 2025 to $20.16 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. This historical growth can be ascribed to several factors, including the rising occurrence of menopausal symptoms, the widespread application of hormone replacement therapy, increasing clinical investigations into neurotransmitter-based treatments, the broadening of women’s health services, and better accessibility to specialty clinics.

The vasomotor menopausal symptoms (vms) treatment market is poised for significant expansion over the upcoming years. Projections indicate it will reach $26.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This anticipated growth during the forecast period stems from several factors, including a surging demand for non-hormonal treatment options, heightened public awareness concerning menopause-related health care, increased financial commitments towards women’s health research, the broadened application of telemedicine for treatment delivery, and advancements in developing cutting-edge VMS therapeutics. Key trends projected for this period encompass the escalating creation of non-hormonal treatments, the expanding embrace of tailored menopause management strategies, the growing reliance on digital health platforms for symptom control, the broadening scope of combination drug regimens, and a sharpened emphasis on long-term safety considerations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

What Key Drivers Are Influencing The Growth Of The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Government efforts aimed at improving women’s health during menopause are anticipated to drive expansion in the vasomotor menopausal symptom’s treatment market in the future. These governmental programs for menopausal well-being include financial support for novel investigations into the menopausal transition, disease prevention, and various pharmacological, clinical, and epidemiological research domains. Such endeavors form a component of wider women’s health strategies addressing a variety of issues. As an illustration, in January 2023, the Government of New South Wales, an Australia-based government body, launched an investment of $40.3 million across four years (2022-2023 to 2025-2026) to establish up to 16 new initiatives designed for women experiencing severe menopausal symptoms. Consequently, the government’s undertakings concerning women’s health in menopause are fueling the expansion of the vasomotor menopausal symptom’s treatment market.

What Major Segment Divisions Exist Within The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

The vasomotor menopausal symptoms (vms) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) By Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) By Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) By Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) By Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

Which Upcoming Trends Are Expected To Influence The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Major companies operating in the vasomotor menopausal symptoms treatment market are developing new products like Veozah and securing approvals to offer fresh treatment options, thereby addressing unmet medical needs for patients. The authorization of novel menopause drugs provides superior efficacy and safety compared to existing therapies. For instance, in May 2023, Astellas Pharma Inc, a Japan-based pharmaceutical company, obtained approval for Veozah (fezolinetant) 45 mg once daily from the Food and Drug Administration (FDA), a US-based federal agency, to treat menopausal vasomotor symptoms (VMS), which span from mild to severe. It is the initial nonhormonal neurokinin 3 (NK3) receptor antagonist authorized for the management of menopausal-related VMS. This hormone-free solution works by blocking a specific pathway in the brain responsible for regulating these symptoms. It offers an alternative treatment for women experiencing these symptoms, particularly those who cannot or choose not to undergo hormone therapy. The endorsement of Veozah emphasizes its potential as a new medication for controlling menopausal symptoms.

Which Companies Are Leading Innovation In The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc

Read the full vasomotor menopausal symptoms (vms) treatment market report here:

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2025. The regions covered in the vasomotor menopausal symptoms (vms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vasomotor Menopausal Symptoms (VMS) Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp

Browse Through More Reports Similar to the Global Vasomotor Menopausal Symptoms (VMS) Treatment Market 2026, By The Business Research Company

Menopausal Hot Flashes Global Market Report

https://www.thebusinessresearchcompany.com/report/menopausal-hot-flashes-global-market-report

Menopause Global Market Report

https://www.thebusinessresearchcompany.com/report/menopause-global-market-report

Vulvodynia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.